IVI and the European Union


European Member States of IVI

Finland, the Netherlands, and Sweden are State Parties of the IVI Establishment Agreement, while Malta and Romania are signatories.


Additional European Union Partners of IVI

IVI has ongoing and historical engagement with partners in Austria, Belgium, Bulgaria, Denmark, France, Germany, Italy, the Slovak Republic, and Spain.

In 2021, IVI and the Joint European Disruptive Initiative (JEDI) signed a Memorandum of Understanding to establish a collaborative relationship, in particular around innovative approaches to zoonoses, infectious diseases and in addressing the global threat of antimicrobial resistance. In addition,

IVI European Regional Office (IERO)

IVI is establishing its first regional outside of its headquarters in Seoul, Korea. The IERO will be based in Stockholm, Sweden and will be responsible for conducting independent and collaborative vaccine research and development projects, as well as engaging the Swedish government, IVI’s other European member countries, and partners from the public and private sectors across the region, including the Karolinska Institute.

The Riksdag of Sweden is slated to vote on the proposed Host Country Agreement for the IERO in 2022. Link to proposal by the Swedish Ministry of Foreign Affairs (In Swedish).

IVI Programs Funded by the European Union

Typhoid Conjugate Vaccine Introduction in Africa program (THECA)

Grant agreement: RIA2017S-2027
Project website

THECA is a consortium led by the University of Cambridge Department of Medicine and funded by a €13 million Euro grant from the European and Developing Countries Clinical Trials Partnership (EDCTP). THECA includes a mass vaccination campaign in the Democratic Republic of the Congo using the Typbar-TCV (Vi-TT) typhoid conjugate vaccine. From 2019-2023, this project will assess the safety, feasibility and cost-effectiveness of Vi-TT and its ability to limit the spread of antimicrobial resistance.

THECA’s European consortium partners include the Institute of Tropical Medicine Antwerp of Belgium and the Mérieux Foundation of France.

Vaccines Against Schistosomiasis for Africa (VASA)

European Union Horizon 2020 Grant: 815643
Project website

With a €6.6 million Euro grant from EU Horizons 2020, The University of Cambridge and IVI launched VASA in 2019 to conduct a Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in Madagascar. This project includes disease surveillance and cost-effectiveness studies, the formation of a global consortium to advance schistosomiasis vaccine research, and an Integrated Product Development Plan (IPDP) for development of the vaccine backed by the Bill and Melinda Gates Foundation.

VASA’s European consortium partners include the Leiden University Medical Center in the Netherlands and the University of Tübingen in Germany.